ACTU

Quote

Short

News

Articles

Message Board

Actuate Therapeutics Inc. (NASDAQ : ACTU ) News

Actuate Therapeutics Inc. (NASDAQ: ACTU) News Releases

ACTU News Releases

June 01, 2026 07:00:00 am

GlobeNewswire

Actuate Therapeutics Announces ASCO Poster Presentations Demonstrating Compelling Clinical and Biomarker Data for Elraglusib in First-Line Metastatic Pancreatic Cancer

May 11, 2026 07:00:00 am

GlobeNewswire

Actuate Therapeutics Announces FDA Clearance of IND for Oral Elraglusib and Strategic Initiatives to Advance the Elraglusib Development Program

May 06, 2026 08:45:00 am

GlobeNewswire

Actuate Therapeutics Announces Key Appointment of Industry Veteran to Board of Directors

April 14, 2026 08:45:00 am

GlobeNewswire

Actuate Therapeutics Announces Nature Medicine Publication of Clinical Trial Results Showing Doubling of the Rate of Survival with Elraglusib Plus Chemotherapy in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma

March 24, 2026 07:00:00 am

ACCESS Newswire

Actuate Therapeutics: Poised for Potential $200M+ Pediatric Priority Review Vouchers and Transformative Combinations in RAS-Driven Cancers

March 19, 2026 10:30:00 am

Baystreet

Targeted Cancer Tech Is Pulling Billions Away From Old-School Oncology

March 19, 2026 07:00:27 am

US Earnings Reports

Expected US Company Earnings on Thursday, March 19th, 2026

March 12, 2026 07:00:22 am

US Earnings Reports

Expected US Company Earnings on Thursday, March 12th, 2026

March 12, 2026 05:30:38 am

US Earnings Reports

Expected earnings - Actuate Therapeutics Inc.

March 09, 2026 08:45:00 am

GlobeNewswire

Actuate Therapeutics Launches Strategic Research Initiative to Combine Elraglusib with RAS Inhibitors

	Next 10

Subscribe to Our Newsletter

Download The Market Wire News App

Link Market Wire News to Your X Account